Pancreatic Cancer Treatment Guidelines

Diagnosis and Staging

The European Society for Medical Oncology recommends CT scan as the preferred imaging modality for initial staging of pancreatic cancer, providing essential information about tumor extent and vascular involvement 1, 3
MRI/MRCP may provide additional information about biliary and pancreatic ducts and can better distinguish solid from cystic masses, particularly in patients with liver or renal failure 3
Endoscopic ultrasound (EUS) is valuable for assessing vascular and nodal involvement and obtaining pathological samples when needed 1, 3
Laparoscopy may detect small peritoneal and liver metastases in approximately 15% of patients, changing treatment strategy, and should be considered before resection of large left-sided tumors or when neoadjuvant treatment is planned 1

Pylorus-preserving pancreaticoduodenectomy is the procedure of choice for pancreatic head tumors, while distal pancreatectomy (typically including splenectomy) is standard for body and tail tumors 2, 4
Achieving negative resection margins (R0) is the most critical prognostic factor for patients undergoing radical resection 3, 4
The experience of the surgical team significantly impacts outcomes, supporting the case for specialized centers 1, 3

For resectable disease (Stage I), radical pancreatic resection remains the standard treatment option, and adjuvant chemotherapy with either 5-fluorouracil (5-FU) or gemcitabine (GEM) for six cycles is recommended following resection 1, 2
For borderline resectable disease (Stage IIA), neoadjuvant approaches (chemotherapy or chemoradiation) may increase R0 resection rates 2, 4
For metastatic disease (Stage IV), FOLFIRINOX has proven superior to gemcitabine alone for patients with good performance status (ECOG 0-1) and normal or near-normal bilirubin levels, despite increased toxicity 5

For biliary obstruction, endoscopic placement of a metallic biliary stent is strongly recommended over percutaneous insertion 5
Duodenal obstruction is preferentially managed by endoscopic placement of an expandable metal stent rather than surgery 5
Pain management is a major priority and should follow standard guidelines, with consideration of radiotherapy for coeliac pain control 5

Intraoperative radiotherapy (IORT) has shown improved local control and overall survival in European centers, particularly in patients with lower tendency for systemic disease spread 2, 4
Molecular biomarkers such as hENT1 may help identify patients more likely to benefit from gemcitabine therapy 6

The FOLFIRINOX regimen, successful in metastatic disease, is being evaluated for potential use in neoadjuvant and adjuvant settings, though its increased toxicity requires careful consideration in trial design 6
Uniform classifications for disease stage, radiological resectability, and treatment results reporting are needed to advance clinical research 7